Metabolic bone disease

AMGEN TO PRESENT DATA AT ACR 2023 ACROSS EXPANDED RHEUMATOLOGY PIPELINE AND PORTFOLIO

Retrieved on: 
Wednesday, November 1, 2023
Janus, Online, Woman, Zoledronic acid, Biologic, Rheumatology, Population Health Management, Metabolic bone disease, Spondyloarthropathy, Systemic disease, Thrombosis, MRI, ANCA, Health care, Syndrome, Immunomodulation, Domain, Metabolism, Risk, Vasculitis, Inflammation, Osteoporosis, Adalimumab, Janus kinase inhibitor, Biomarker, Crystal, Rheumatoid arthritis, Alendronic acid, Social, Psoriatic arthritis, Use, Driver, Etanercept, PST, Metric, State, Paint, Pharmaceutical industry, Medical imaging, Health insurance, Book, Dentistry, Dietary supplement, Denosumab, Patient, Hand

THOUSAND OAKS, Calif., Nov. 1, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new scientific and clinical research across its expanded rheumatology pipeline and portfolio, following the recent acquisition of Horizon Therapeutics. More than 20 abstracts will be presented during the American College of Rheumatology (ACR) Convergence 2023, taking place Nov. 10-15, in San Diego.

Key Points: 
  • Abstract #2161, Poster Session C: RA – Treatments Poster III, Tuesday, Nov. 14 from 9-11am PST
    Outcomes in Patients With Rheumatoid Arthritis Initiating Therapy With Etanercept, Adalimumab, or Janus Kinase Inhibitors
    Abstract #0441, Poster Session A: RA – Treatments Poster I, Sunday, Nov. 12 from 9-11am PST
    Treatment-Emergent Major Adverse Cardiovascular and Thromboembolic Events Were Infrequent During Pegloticase Therapy: Pooled Clinical Trial Findings
    Abstract #0236, Poster Session A: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I, Sunday, Nov. 12 from 9-11am PST
    Oral Urate-Lowering Therapy Use and Efficacy Following Pegloticase Treatment: Findings from a Rheumatology Network Database
    Abstract #0237, Poster Session A: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I, Sunday, Nov. 12 from 9-11am PST
    Abstract #0239, Poster Session A: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I, Sunday, Nov. 12 from 9-11am PST
    Abstract #0242, Poster Session A: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I, Sunday, Nov. 12 from 9-11am PST
    Finding Lost-to-Care Gout Patients in a Large Community Rheumatology Network: Patient Re-engagement Initiative with Metrics (PRIME)
    Abstract #1102, Poster Session B: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II, Monday, Nov. 13 from 9-11am PST
    Abstract #1103, Poster Session B: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II, Monday, Nov. 13 from 9-11am PST
    Abstract #1107, Poster Session B: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II, Monday, Nov. 13 from 9-11am PST
    Abstract #1108, Poster Session B: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II, Monday, Nov. 13 from 9-11am PST
    Real-world Trends in the Use of Immunomodulation as Co-Therapy to Pegloticase: Claims-Based Findings Since 2016
    Abstract #1123, Poster Session B: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II, Monday, Nov. 13 from 9-11am PST
    Abstract #1145, Poster Session B: Miscellaneous Rheumatic & Inflammatory Diseases Poster II, Monday, Nov. 13 from 9-11am PST
    Understanding Community Perspectives on Disease Management: A Social Media Analysis of Gout Care Strategies
    Abstract #1691, Oral Abstract Session: Spondyloarthritis Including Psoriatic Arthritis – Treatment II: PsA, Monday Nov. 13 from 5-5:10pm PST
    Apremilast Reduces Inflammation as Measured by MRI of the Hand in Patients With Psoriatic Arthritis: Primary Results from the Phase 4 MOSAIC Study
    Abstract #1690, Oral Abstract Session: Spondyloarthritis Including Psoriatic Arthritis – Treatment II: PsA, Monday Nov. 13 from 4:45-4:55pm PST
    Abstract #0966, Poster Session B: Epidemiology & Public Health Poster II, Monday Nov. 13 from 9-11am PST
    Abstract #1041, Poster Session B: Imaging of Rheumatic Diseases Poster I, Monday Nov. 13 from 9-11am PST
    Effect of Apremilast Treatment on the Domains of MDA-Joints in Patients With Early Oligoarticular Psoriatic Arthritis: 16-Week Results From FOREMOST
    Abstract #1413, Poster Session B: Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II: SpA, Monday Nov. 13 from 9-11am PST
    Abstract #1414, Poster Session B: Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II: SpA, Monday Nov. 13 from 9-11am PST
    Current Trends in the Risk of Subsequent Fracture After Initial Fracture, and Post-Fracture Treatment Among Commercially Insured Postmenopausal Women in the United States
    Abstract #2528, Oral Abstract Session: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science, Tuesday, Nov. 14 from 4:15-4:25pm PST
    Comparative Effectiveness of Denosumab versus Zoledronic Acid Among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program
    Abstract #2529, Oral Abstract Session: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science, Tuesday, Nov. 14 from 4:30-4:40pm PST
    Comparative Effectiveness of Denosumab versus Alendronate among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program
    Abstract #2008, Poster Session C: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster, Tuesday, Nov. 14 from 9-11am PST
    Abstract #0683, Poster Session A: Vasculitis – ANCA-Associated Poster I: Treatment Outcomes, Sunday, Nov. 12 from 9-11am PST
    Abstract #0684, Poster Session A: Vasculitis – ANCA-Associated Poster I: Treatment Outcomes, Sunday, Nov. 12 from 9-11am PST
    Abstract #0685, Poster Session A: Vasculitis – ANCA-Associated Poster I: Treatment Outcomes, Sunday, Nov. 12 from 9-11am PST
    Abstract #0686, Poster Session A: Vasculitis – ANCA-Associated Poster I: Treatment Outcomes, Sunday, Nov. 12 from 9-11am PST
    Abstract #2379, Poster Session C: Vasculitis – ANCA-Associated Poster III: Biomarkers & Renal Outcomes, Tuesday, Nov. 14 from 9-11am PST
    Abstract #0171, Poster Session A: Health Services Research Poster I, Sunday, Nov. 12 from 9-11am PST
    Dazodalibep, a CD40L Antagonist, in Subjects with Sjögren's Having Moderate-to-Severe Systemic Disease Activity: Full Crossover Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study
    Abstract #1636, Oral Abstract Session: Sjögren's Syndrome – Basic & Clinical Science, Monday, Nov. 13 from 2-3:30pm PST
    Abstract #1638, Oral Abstract Session: Sjögren's Syndrome – Basic & Clinical Science, Monday, Nov. 13 from 2-3:30pm PST
    Treatment Patterns and Drivers of Biologic Prescriptions in Patients with Primary Sjögren's Disease: Results from a Multinational, Real-World Survey
    Abstract #1369, Poster Session B: Sjögren's Syndrome – Basic & Clinical Science Poster I, Monday, Nov. 13 from 9-11am PST
    Population Pharmacokinetic/Pharmacodynamic Modeling of Dazodalibep, a CD40L Antagonist, in Healthy Volunteers and Patients with Rheumatoid Arthritis and Sjögren's Syndrome
    Abstract #1379, Poster Session B: Sjögren's Syndrome – Basic & Clinical Science Poster I, Monday, Nov. 13 from 9-11am PST
    Disease Burden of Patients with Primary Sjögren's Disease: Results from a Multinational Real-World Survey
    Abstract #2179, Poster Session C: Sjögren's Syndrome – Basic & Clinical Science Poster II, Tuesday, Nov. 14 from 9-11am PST
    Osteoporosis Treatment Attributes and Levels for an Online Decision-Making Tool for Patients: Findings from Adaptive Choice-Based Conjoint Analysis
    Abstract #0688, Poster Session A: Vasculitis – ANCA-Associated Poster I: Treatment Outcomes, Sunday, Nov. 12 from 9-11am PST

Amolyt Pharma Announces Data on Prevalence of Bone Disease in Patients with Hypoparathyroidism and Favorable Bone Effects of Eneboparatide at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting

Retrieved on: 
Monday, October 16, 2023
Annual general meeting, Calcium, Hypoparathyroidism, McMaster University, Bone fracture, Bone disease, Society, American Society for Bone and Mineral Research, PTHR1, Homeostasis, Fracture, Phase 3, Osteoporosis, Medicine, DXA, Patient, PMF, Metabolic bone disease, Woman, Osteopenia, Quality of life, Medical imaging, Dietary supplement

LYON, France, and CAMBRDIGE, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced data from two posters that were presented at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting, which is being held October 13-16, 2023, in Vancouver, BC, Canada. The data include a prospective analysis of bone disease in patients with hypoparathyroidism from the Canadian National Hypoparathyroidism Registry with evidence of significant bone disease burden in postmenopausal females (PMF). In addition, data from both pre-clinical and clinical studies of eneboparatide continue to demonstrate its ability to restore balanced bone turnover, preserving bone integrity, while maintaining calcium homeostasis and normalizing urinary calcium.

Key Points: 
  • The data include a prospective analysis of bone disease in patients with hypoparathyroidism from the Canadian National Hypoparathyroidism Registry with evidence of significant bone disease burden in postmenopausal females (PMF).
  • In addition, data from both pre-clinical and clinical studies of eneboparatide continue to demonstrate its ability to restore balanced bone turnover, preserving bone integrity, while maintaining calcium homeostasis and normalizing urinary calcium.
  • “We’re very pleased to have a strong presence at this year’s ASBMR Annual Meeting.
  • These data increase our understanding of the relationship between hypoparathyroidism and bone strength.

Amolyt Pharma Announces Two Poster Presentations at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting

Retrieved on: 
Tuesday, October 3, 2023
American Society for Bone and Mineral Research, Metabolic bone disease, McMaster University, Society, Annual general meeting, Communications satellite

LYON, France, and CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that it will present two posters at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting, which is being held October 13-16, 2023 in Vancouver, BC, Canada.

Key Points: 
  • LYON, France, and CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that it will present two posters at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting, which is being held October 13-16, 2023 in Vancouver, BC, Canada.
  • Details of the presentations are as follows:
    Session Time: 1:30 – 3:00 p.m. PT (4:30 – 6:00 p.m.
  • ET)
    Author/Presenter: Salma Hussein, M.D.
  • (Clinical Fellow of Metabolic Bone Disease, McMaster University)
    Title: Eneboparatide, A Novel Investigational PTH1R Agonist, Maintains Calcium Homeostasis Without Deleterious Effects on Bone
    Session Time: 1:30 – 3:00 p.m. PT (4:30 – 6:00 p.m.

The Shriners Hospitals for Children - Canada Research Centre celebrates half a century of existence

Retrieved on: 
Thursday, August 17, 2023
Dentistry, Parent, Teaching, Anxiety, Research institute, Quality of life, Bone, Collagen, type I, alpha 1, OC, Research, Medicine, Bone disease, Health, Doctor of Philosophy, Government, Pain, DSM-IV codes, International Clinical Research Center, Metabolic bone disease, Student, MD, Physician, Shriners Hospitals for Children, McGill University, Virtual reality, Knowledge, Diagnosis, McGill University Health Centre, X-linked hypophosphatemia, Nursing research, MRC Human Genetics Unit, Shriners, Hormone replacement therapy, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Nursing, Child

So research into mineralized tissue has always been a strength in Quebec," explains Professor René St-Arnaud, PhD, Director of the Research Center.

Key Points: 
  • So research into mineralized tissue has always been a strength in Quebec," explains Professor René St-Arnaud, PhD, Director of the Research Center.
  • In 1973, following the integration of Shriners Hospitals for Children – Canada into the Quebec health care network, Shriners Children’s management, with the approval of the provincial government, created the first Research Centre within its hospital network.
  • The Shriners Hospital for Children - Canada Research Centre is constantly developing new ways to care for children.
  • To mark this 50th anniversary at Shriners Hospital for Children – Canada, Dr. St-Arnaud hosted a scientific seminar yesterday featuring a number of prestigious speakers.

Relation Therapeutics announces launch of flagship integrated wet–dry laboratory at the heart of London’s Knowledge Quarter

Retrieved on: 
Wednesday, February 22, 2023
Biotechnology, Technology, Other Health, Health, Pharmaceutical, Other Science, Research, Software, Artificial Intelligence, Genetics, Science, Knowledge, Therapy, Protein, GSK, Osteoporosis, Francis Crick Institute, Disease, Heart, Knowledge Quarter, Acquisition, Gene, Risk, Drug discovery, Khosla Ventures, Crick, Patient, Refractory, Probability, Machine learning, Francis Crick, Chairperson, Novartis, Metabolic bone disease, Roche, CSO, Fracture, Pharmaceutical industry, Relation

Relation Therapeutics, a leader in the use of high-resolution biology, machine learning and clinical insights to discover life-changing medicines, announced today the opening of their flagship integrated wet–dry laboratory.

Key Points: 
  • Relation Therapeutics, a leader in the use of high-resolution biology, machine learning and clinical insights to discover life-changing medicines, announced today the opening of their flagship integrated wet–dry laboratory.
  • The laboratory and offices comprise 5,500 sq ft, located at the heart of London’s Knowledge Quarter, in close reach of collaborators and partners including globally renowned academic research centres and major pharma companies.
  • The new space is another step forward in realising Relation’s ambition to establish a novel transformational approach to drug discovery.
  • The integrated wet–dry laboratory’s unique value for drug discovery comes from efficiently combining the most sophisticated functional genomic techniques with extraordinary computational power and machine learning.

NCQA Releases White Paper on Improving Osteoporosis Care

Retrieved on: 
Friday, July 15, 2022
Information set, Bone fracture, Facebook, Osteoporosis, National Committee, Woman, Patient, LinkedIn, Solution, National Committee for Quality Assurance, GLOBE, Twitter, Geriatrics, Fracture, Telehealth, NCQA, Healthcare Effectiveness Data and Information Set, Caregiver, Quality assurance, Ageing, Confusion, Pharmacist, Risk, Prevalence, Round Table, Diagnosis, DXA, Population health, Metabolic bone disease, Man, Population, Dietary supplement, Health insurance, Risk management, Dentistry, Amgen

WASHINGTON, July 14, 2022 (GLOBE NEWSWIRE) -- The National Committee for Quality Assurance (NCQA) today announced the release of a new white paper titled, " Improving Osteoporosis Care ," with recommendations for improving osteoporosis screening and management.

Key Points: 
  • WASHINGTON, July 14, 2022 (GLOBE NEWSWIRE) -- The National Committee for Quality Assurance (NCQA) today announced the release of a new white paper titled, " Improving Osteoporosis Care ," with recommendations for improving osteoporosis screening and management.
  • The white paper summarizes findings from a roundtable meeting convened by NCQA and funded by Amgen in January 2022 in which clinicians, osteoporosis researchers, and health plan leaders discussed how to improve osteoporosis care.
  • "With this white paper, NCQA is proud to share actionable recommendations for improving systems and policies, as well as screening and interventions, which can help reduce care gaps and improve the quality of osteoporosis care."
  • To improve osteoporosis prevention, diagnosis, and treatment, NCQA sought input from osteoporosis researchers, clinicians who care for patients with osteoporosis, and health plan leaders who direct osteoporosis performance measurement and quality improvement.

Radius Health Provides Business Update on Bone Health

Retrieved on: 
Tuesday, March 8, 2022
Doctor of Philosophy, Lists of diseases, Metabolic bone disease, Risk, Private Securities Litigation Reform Act, Regulation of tobacco by the U.S. Food and Drug Administration, Prader–Willi syndrome, Literature, Patient, Research, Massachusetts General Hospital, Patent, Woman, Bone health, PTH, VP, Food, Security (finance), Discovery Science, Annual report, Hospital, U.S. Securities and Exchange Commission, Fortnight, Program, MGH, SEC, IP, COVID-19, Man, United States patent law, Ma Sik-chun, Fracture, Male, History, Angelman syndrome, Partnership, United States Patent and Trademark Office, USPTO, Parathyroid hormone, Spasm, Department, Bone fracture, Media relations, Osteoporosis, GLOBE, NASDAQ, RAD1901, Pharmaceutical industry, Medical device, Dietary supplement, Public relations, Radius

TYMLOS IP: additional patent issued that extends patent protection to January 10, 2040

Key Points: 
  • TYMLOS IP: additional patent issued that extends patent protection to January 10, 2040
    BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Radius or the Company) (NASDAQ: RDUS) provided an update on business development and intellectual property progress in its Bone Health franchise.
  • Dr. Marc Wein M.D., Ph.D., investigator in the Department of Endocrinology at Massachusetts General Hospital with clinical focus on osteoporosis and metabolic bone diseases is the main collaborator with Radius.
  • Dr. Weins research first described the role of SIKs in mediating the actions of parathyroid hormone (PTH) in bone.
  • Radius is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology.

SiSaf Announces Michael J. Econs MD, World-leading Expert in Metabolic Bone Disease, as Clinical Advisor

Retrieved on: 
Thursday, January 27, 2022
Osteoclast, Therapy, Trial of the century, Patient, Knowledge, RNA, Bone, Neoplasm, XLH, Lists of diseases, Metabolism, Lipid, Research, Silicon, Gamma ray, X-linked hypophosphatemia, Indiana University School of Medicine, Economics, CEO, Osteomalacia, Vickers Venture Partners, Company, Genetic distance, Interferon, IND, Autosome, MD, Disease, CLCN7, Metabolic bone disease, Pharmaceutical industry, Vaccine, Medical imaging, Medicine, Endocrinology, FGF23

GUILDFORD, England, Jan. 27, 2022 /PRNewswire/ -- SiSaf Ltd, a company developing RNA therapeutics for rare genetic skeletal disorders, today announced that it has appointed Professor Michael J. Econs, MD as Clinical Advisor.

Key Points: 
  • GUILDFORD, England, Jan. 27, 2022 /PRNewswire/ -- SiSaf Ltd, a company developing RNA therapeutics for rare genetic skeletal disorders, today announced that it has appointed Professor Michael J. Econs, MD as Clinical Advisor.
  • Although this did not show clinical benefit , the experience gained will be invaluable in guiding SiSaf in its clinical studies."
  • SiSaf is using these next-generation lipid nanoparticles to advance an in-house pipeline of RNA therapeutics for rare genetic skeletal disorders.
  • SiSaf is a private company supported by venture capital investors including Vickers Venture Partners & UK Future Fund.

SiSaf Announces Michael J. Econs MD, World-leading Expert in Metabolic Bone Disease, as Clinical Advisor

Retrieved on: 
Thursday, January 27, 2022
Osteoclast, Therapy, Trial of the century, Patient, Knowledge, RNA, Bone, Neoplasm, XLH, Lists of diseases, Metabolism, Lipid, Research, Silicon, Gamma ray, X-linked hypophosphatemia, Indiana University School of Medicine, Economics, CEO, Osteomalacia, Vickers Venture Partners, Company, Genetic distance, Interferon, IND, Autosome, MD, Disease, CLCN7, Metabolic bone disease, Pharmaceutical industry, Vaccine, Medical imaging, Medicine, Endocrinology, FGF23

GUILDFORD, England, Jan. 27, 2022 /PRNewswire/ -- SiSaf Ltd, a company developing RNA therapeutics for rare genetic skeletal disorders, today announced that it has appointed Professor Michael J. Econs, MD as Clinical Advisor.

Key Points: 
  • GUILDFORD, England, Jan. 27, 2022 /PRNewswire/ -- SiSaf Ltd, a company developing RNA therapeutics for rare genetic skeletal disorders, today announced that it has appointed Professor Michael J. Econs, MD as Clinical Advisor.
  • Although this did not show clinical benefit , the experience gained will be invaluable in guiding SiSaf in its clinical studies."
  • SiSaf is using these next-generation lipid nanoparticles to advance an in-house pipeline of RNA therapeutics for rare genetic skeletal disorders.
  • SiSaf is a private company supported by venture capital investors including Vickers Venture Partners & UK Future Fund.

Radius Announces Update on TYMLOS® (abaloparatide) Label

Retrieved on: 
Thursday, December 23, 2021
Caregiver, Media relations, U.S. Securities and Exchange Commission, Physician, Annual report, Bone fracture, Contraindication, Risk, FDA, Patient, Lactation, Warning, Palpitations, Private Securities Litigation Reform Act, Pregnancy, Kidney stone disease, Orthostatic hypotension, Human, Primary hyperparathyroidism, Hypercalciuria, Regulation of tobacco by the U.S. Food and Drug Administration, Tachycardia, Partnership, PTH, NASDAQ, Dizziness, Adult, Neuroscience, Fracture, SEC, Nausea, Senior, COVID-19, Anaphylaxis, Parathyroid hormone, Incidence, History, Headache, Skeleton, Vertigo, Fatigue, Kidney, Osteoporosis, Security (finance), GLOBE, Food, Woman, Metabolic bone disease, Breathe Me, Hives, Dietary supplement, Pharmaceutical industry, Medical imaging, Vaccine, Public relations, Hypercalcaemia, Osteosarcoma, Radius

FDA approved the removal of the boxed warning from the TYMLOS label, effective December 22, 2021

Key Points: 
  • FDA approved the removal of the boxed warning from the TYMLOS label, effective December 22, 2021
    BOSTON, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Radius or the Company) (NASDAQ: RDUS) today announced that the U.S. Food and Drug Administration (FDA) has approved updates to the TYMLOS label, including the removal of the boxed warning regarding the risk of osteosarcoma.
  • Bruce Mitlak, M.D., the Chief Medical Officer of Radius, commented, This is an important update to the TYMLOS label.
  • Dr. Mitlak continued, This action and subsequent label change will provide both physicians and their patients with valuable information regarding individual treatment decisions.
  • Shah continued, We remain focused on exploring additional label adjustment opportunities for TYMLOS and, in that regard, maintain an ongoing dialogue with the FDA around additional data.